This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Beverly Merz

JAMA. 1988;259(7):957-958.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

TWO CLINICAL TRIALS based on blocking tumor-cell growth factors represent an approach that may transform the face of cancer chemotherapy within the next decade.

The phase I studies now under way at the National Cancer Institute, Bethesda, Md, and Memorial Sloan-Kettering Cancer Center, New York City, involve antibodies to growth factors and their receptors. Because these agents intercede in a particular process in a particular type of tumor cell, they have potentially greater specificity and fewer side effects than the tumoricidal agents currently in use. Thus they may make it much easier to spare the patient and spoil the tumor.

The first of these agents—a monoclonal antibody to gastrin-releasing peptide (GRP)—has been in phase I clinical trials for 18 months. The antibody, manufactured by Hybritech in San Diego, is raised to bombesin, a regulatory peptide isolated from frog skin. Bombesin is the amphibian analogue of GRP, which stimulates human bronchial . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?